ADELAIDE, Australia / RankWire.AI / – A breakthrough by Australian scientists has identified a molecular switch that controls the dissemination of highly aggressive tumors, paving the way for innovative treatments to prevent secondary cancers. The discovery is detailed in EMBO Molecular Medicine, where researchers from Adelaide University and the Olivia Newton-John Cancer Research Institute showed that re-establishing a crucial regulatory molecule called miR-342 greatly diminishes tumor metastasis. These results highlight a promising new strategy to address triple-negative breast cancer by targeting dormant cancer cells before they form deadly secondary tumors in distant organs.
In Australia, triple-negative breast cancer makes up between 10% and 15% of the roughly 21,000 new breast cancer cases diagnosed each year. Although it accounts for a smaller proportion of cases, it results in a disproportionately high number of fatalities. This subtype of breast cancer lacks estrogen, progesterone, and HER2 receptors, which makes standard hormone-targeted treatments ineffective. The study’s lead researchers revealed that when levels of miR-342 decline, it triggers an overactivation of a cancer-promoting pathway called E2F, enabling dormant cancer cells to spread and form dangerous secondary tumors throughout the body.
New Targeted Treatments Offer Hope for Preventing High-Risk Metastasis
Using pre-clinical models, the team demonstrated that increasing miR-342 levels substantially reduced the migration of cancer cells to distant organs. Additionally, they found that palbociclib, a CDK4/6 inhibitor already approved for hormone receptor-positive breast cancers, significantly curtailed metastatic tumor growth in models with low miR-342 expression. These insights suggest that assessing miR-342 levels could enable clinicians to repurpose existing drugs for high-risk patients.
Associate Professor Philip Gregory, co-senior author from the Adelaide University’s Centre for Cancer Biology, confirmed that preventing metastasis remains the biggest hurdle in effectively treating aggressive breast cancers. Gregory emphasized that since palbociclib targets the hyperactive E2F pathway, administering the drug after cancer cells have already spread can prevent microscopic deposits from enlarging. This approach shifts the focus from merely shrinking primary tumors to stopping microscopic secondary cancers from evolving into life-threatening conditions.
Pre-Clinical Results Published in Peer-Reviewed Journal EMBO Molecular Medicine
The research team pointed out that the biological diversity of triple-negative breast cancer has historically impeded the development of universal targeted therapies. By identifying a specific biological vulnerability shared by a particular patient subgroup, the study opens new possibilities for personalized treatment options. As Australian scientists continue to explore this promising approach, efforts are underway to validate the findings using patient-derived models ahead of clinical trials.
Cancer specialists and research organizations across Australia expressed optimism about the findings, stressing the urgent need for expanded treatment options when primary therapies are ineffective. The research team intends to collaborate with international clinical networks to expedite biomarker screening processes. Confirming the effectiveness of miR-342 testing could soon allow clinicians to identify patients suitable for targeted CDK4/6 inhibitor treatments during early intervention stages.